Many adenocarcinomas, including colorectal cancer (CRC), overexpress the MUC13 cell surface mucin, but the functional significance and mechanisms are unknown. Here, we report the roles of MUC13 in colonic tumorigenesis and tumor progression. High-MUC13 expression is associated with poor survival in two independent patient cohorts. In a comprehensive series of in vivo experiments, we identified a critical role for MUC13 in the development of this malignancy, by promoting survival and proliferation of tumor-initiating cells and driving an immunosuppressive environment that protects tumors from checkpoint inhibitor immunotherapy. In Muc13-deficient mice, fewer tumors are generated after exposure to carcinogens and inflammation, they have markedly reduced β-catenin signaling, have more tumor-infiltrating CD103 + dendritic cells and CD8 + T lymphocytes, fewer myeloid-derived suppressor cells, and are rendered sensitive to checkpoint inhibitor immunotherapy (anti-PD-L1). Mechanistically, we show that MUC13 protects β-catenin from degradation, by interacting with GSK-3β, which increases β-catenin nuclear translocation and promotes its signaling, thereby driving cancer initiation, progression, invasion, and immune suppression. Therefore, MUC13 is a potential marker of poor prognosis in colorectal cancer, and inhibiting MUC13 may be useful in the treatment of colitis-associated cancer and sensitizing tumors to immunotherapy.
Introduction
Despite recent advances in therapy, colorectal cancer (CRC) is still the second leading cause of cancer death globally due to metastasis and posttreatment recurrence [1, 2] . The development of CRC is attributed to both environmental and genetic factors with only 1-5% of CRC due to heritable syndromes, and most cancers evolve in a multistage process involving multiple genes [3] . Understanding the oncogenic role of overexpressed proteins that promote CRC progression and metastasis is essential for developing innovative therapies.
Hyperactivated Wnt/β-catenin signaling is considered as a hallmark of colorectal tumorigenesis [4, 5] , and has been recently implicated in immune evasion [6] , immunosuppression [7] , and impaired immune surveillance [8] . The primary event during Wnt signaling is β-catenin stabilization leading to its nuclear translocation and activation of transcription factors. In the absence of activated Wnt signaling, a multiprotein complex consisting of the core proteins AXIN, adenomatous polyposis coli (APC), and glycogen synthase kinase 3β (GSK3β) regulates cellular β-catenin [9] by engaging β-catenin and mediating sequential phosphorylation by GSK-3β. Phosphorylated β-catenin is then recognized by the β-TrCP ubiquitin ligase followed by proteasomal degradation [9] . In the presence of Wnt ligand, β-catenin disengages from the multiprotein complex, escaping phosphorylation by GSK-3β and degradation, accumulates in the cytosol and translocates to the nucleus where it interacts with T cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors to induce target gene expression. In CRC, 90% of all tumors have a mutation in a key regulatory factor of the Wnt/β-catenin pathway. Mutational inactivation of APC results in increased β-catenin accumulation and signaling and is an early event in the progression of CRC [10] . However, inactivation of APC alone does not appear sufficient to fully activate Wnt signaling or to convey an invasive and metastatic behavior in tumor cells [11, 12] . It is likely that other mutational events or extrinsic factors may be necessary for maximal activation of the Wnt pathway to promote invasion and metastasis.
Mucins are complex cell surface and secreted glycoproteins that provide protection and lubrication to the epithelial surface of mucosal tissues [13, 14] . Aberrant expression of cell surface mucins occurs in many cancers and has been linked to the initiation, progression, and poor prognosis of multiple types of adenocarcinoma [15, 16] .
The MUC13 cell surface mucin is overexpressed in gastric [17] , colorectal [18] [19] [20] , pancreatic [21, 22] , renal [23] , and ovarian [24] cancers. Normally this protein is expressed on the apical borders of epithelial cells, including the luminal surface glycocalyx of enterocytes and goblet cells in the intestine [25] , with increased cytoplasmic expression in infection [26] and inflammation [27, 28] . High cytoplasmic MUC13 expression is associated with CRC metastasis and correlates with nuclear factor-κB (NFκB) expression in metastases [29] . MUC13 has a 69 amino acid cytoplasmic domain that includes eight serine and two tyrosine residues for potential phosphorylation, and a protein kinase C consensus phosphorylation motif [25] that could play a critical role in tumorigenesis via cell signaling pathways regulating apoptosis and proliferation [19, 24, 25, 27] . We have previously shown that MUC13 protects cancer cells from death by promoting activation of NFκB [29] and silencing MUC13 sensitizes colorectal and renal cancer cells to multiple types of therapeutic killing in vitro and in vivo-rendering MUC13 a potential therapeutic target [23, 29] . However, the role of MUC13 in cancer development and progression remains unclear. Here, we report a novel role of MUC13 in promoting colonic tumorigenesis by stabilizing β-catenin, underlining its potential as a therapeutic target in CRC.
Results

High-MUC13 expression in CRC is associated with poor survival
To determine the association of MUC13 expression with clinical outcomes, we analyzed MUC13 expression on a tissue microarray (TMA) of human CRC. High-MUC13 expression was associated with a significantly lower 5-year survival of 45% compared with 90% in individuals with low-MUC13 expressing tumors (P = 0.0006; Fig. 1a and Supplementary Table S1 ). In a second independent cohort High-MUC13 expression in CRC is associated with poor survival in two independent cohorts. a Overall survival in patients from BioMax cohort (Cat. No HCol-Ade180Sur-02; Colon cancer tissue array with survival data) with low or high level MUC13 expression determined by immunohistochemistry; the stained slides were scored by a histopathologist (RL) according to a scoring systems as follows: the proportion of positive cancer cell staining was graded 0 (negative), <25% (1+), 25-50% (2+), 50-70% (3+), and >75% (4+); and the staining intensity of cancer cells was graded as negative (0), weak (1+), moderate (2+), strong (3+), or very strong (4+). The proportion and intensity scores were added to give an overall staining score.
Staining scores ≥5 were classified as high-MUC13 expression, whilst scores ≤4 were considered low-MUC13 expression. (n = 88). Logrank P-value shown. b Overall survival in patients from TCGA cohort. Overall survival (OS) information was obtained from GDC release 9.0 (released on the 25th of October 2017). Primary colorectal cancer patients who had not achieved remission (CDE: 3103479; ther-apy_ongoing status) were assigned into two subgroups, with low (n = 200) and high-MUC13 mRNA expression (n = 50). The MUC13 high expression subgroup was defined as the top 20% of the gene's expression range within the cohort. Log-rank P-value shown (GDC TCGA-COAD), high-MUC13 mRNA expression was significantly associated with poorer overall survival (OS), with a 5-year survival of 37% compared with 70% in the low-MUC13 expression group (P = 0.046, Fig. 1b and Supplementary Table S2 ).
Muc13 promotes colitis-associated tumorigenesis
To ascertain the roles of MUC13 in tumorigenesis, we used an established mouse model of colitis-associated colorectal tumorigenesis (CAC) induced by AOM, followed by DSS, in which colon tumors develop after 84 days ( Fig. 2a ) [30] . Muc13 deficiency in this model resulted in significantly fewer and smaller tumors throughout the colon and lower colon weights compared with wild-type (WT) mice ( Fig.  2b-d ). Furthermore, Muc13 −/− tumors had significantly lower BrdU + proliferative cells than WT tumors ( Fig. 2e ). Histopathological analysis revealed that Muc13 −/− mice exhibited decreased hyperplasia and aberrant crypt foci (indicators of pre neoplasms) in the mid and distal colon ( Fig. 2f ). Muc13 −/− mice also had a greater prevalence of low-grade dysplasia, and a lower prevalence of high-grade dysplasia with no invasion seen ( Fig. 2f , g), whereas~25% of WT tumors had high-grade dysplasia with frequent invasion into submucosa ( Fig. 2f, g) . These results suggest that MUC13 promotes colorectal tumorigenesis.
Muc13 promotes survival and proliferation of intestinal epithelial cells during early tumor development
Differences in tumor multiplicity and load in the CAC model may be explained by altered proliferation and/or death of tumor progenitors arising from the AOM/inflammation-induced DNA damage. To investigate the cellular mechanisms underpinning MUC13-dependent promotion of colorectal tumorigenesis, we first examined whether Muc13 expression protects epithelial cells from death after AOMinduced DNA damage and promotes the proliferation of mutated cells during early tumor formation ( Fig. 3a ). We used terminal deoxynucleotidyl transferase-mediated dUTP nick-end-labeling (TUNEL) to examine the DSS-induced apoptotic response in AOM/DSS-treated mice. Apoptotic cell numbers were significantly higher in Muc13 −/− mice relative to WT control (Fig. 3b ), and biochemical analysis confirmed caspase-3 cleavage consistent with increased apoptosis in Muc13 −/− mice ( Fig. 3c ). However, despite the increased cell death, there were a similar number of DNAdamaged cells detected by γ2H2X2 ( Fig. 3d, e ). The antiapoptotic protein Bcl-XL was induced in WT mice ( Fig.  3d ), confirming previous findings that Bcl-XL is induced by AOM/DSS treatment [31, 32] . In contrast, Bcl-XL was not induced in Muc13 −/− mice, consistent with increased apoptosis ( Fig. 3d ) and with our previous finding that MUC13 protects cells from apoptosis by upregulation of Bcl-XL [29] .
We next asked whether Muc13 also regulated cellular proliferation during the mucosal regeneration stage following exposure to AOM and DSS by analysing colons 16 days after injection of AOM (4 days after cessation of the first administration of DSS) ( Fig. 3f ). Despite the lower amount of cell death observed at day 12 in WT colons, at day 16 we found higher numbers of BrdU + proliferative cells per crypt in the colons of WT mice (Fig. 3g ). Importantly there was no intrinsic difference in proliferation between untreated WT and Muc13 −/− mice ( Fig. 3g ). Therefore, after exposure to mutagens and inflammation, Muc13 enhances the proliferation of epithelial cells and increases their resistance to apoptosis with potential effects on tissue regeneration and tumor formation.
We next tested whether blocking Bcl-XL would reduce tumor development using ABT-263, an orally bioavailable small molecule Bcl-XL inhibitor currently being evaluated in clinical trials. ABT-263 inhibits Bcl-XL function and induces apoptosis in LS513 cells, as evidenced by the release of cytochrome c from mitochondria ( Supplementary  Fig. S1 ). However, Bcl-XL inhibition did not decrease the number of colitis-associated tumors in WT or Muc13 −/− mice, while the previously observed decrease in tumor incidence in Muc13 −/− mice was maintained ( Fig. 3h ).
Muc13 promotes proliferation through β-catenin accumulation and transcriptional activity in CAC tumors
To further define the mechanism by which MUC13 impacts tumorigenesis, we explored relevant pathways known to be important in colonic carcinogenesis. We previously showed that MUC13 enhances NF-κB signaling in response to DNA damage in CRC cell lines [29] . Thus, we examined NF-κB activation after 84 days of AOM/DSS treatment and found that WT tumors had significantly higher NF-κB activity compared with Muc13 −/− tumors ( Fig. 4a ). Next, we examined the phosphatidylinositol 3-Kinase-AKT pathway, which has a major role in cancer development, cell proliferation and survival [33] , but found no difference in Akt phosphorylation between WT and Muc13 −/− mice (Fig. 4a ).
The Wnt/β-catenin pathway plays a critical role in colorectal tumorigenesis and β-catenin itself is frequently mutated in AOM/DSS tumors, resulting in accumulation and altered subcellular distribution [32] . Therefore, we analyzed β-catenin by immunohistochemistry and observed much higher cytoplasmic and particularly strong nuclear β-catenin localization in WT tumors compared with Muc13 −/− tumors in which β-catenin was typically restricted to discrete basolateral areas of the cytoplasm/cellular junctions ( Fig. 4b ). Quantitative analysis confirmed significantly higher β-catenin staining as a percentage of tumor area and intensity in WT tumors (Fig. 4b ). Western blots using an antibody specific to nonphosphorylated β-catenin further verified higher levels of β-catenin in WT tumors (Fig. 4c ). These data suggest that either Muc13 is required for the activation and nuclear translocation of β-catenin in AOM/DSS-induced colonic tumors or tumors carrying activating mutations in the β-catenin pathway do not survive in the absence of Muc13.
To gain insight into the consequences of Muc13promoted β-catenin activity, we assessed the relationship between β-catenin expression in AOM WT and Muc13 −/− tumors on β-catenin target genes. Higher levels of cyclin D1 and C-Jun (drivers of cell cycle G1/S-phase transition and involved in DNA damage repair), matrix metalloproteinase (MMP)-7 (thought to have an oncogenic function in colonic tumorigenesis [34, 35] ), and Smad2/3 (responsible for downstream signaling from the TGFβ-receptor [36] ) were seen within the tumors that express Muc13 and correlated very strongly with β-catenin expression ( Fig. 4c ). Taken together, these data suggest that Muc13 promotes tumor cell proliferation and migration by regulating β-catenin transcriptional activity.
To further dissect the mechanism by which MUC13 promotes β-catenin activity, we examined the effect of MUC13 silencing on β-catenin nuclear translocation in human colon cancer cell lines LS513 (which bears an activating mutation in β-catenin) and HT29 (which is WT for β-catenin but contains an APC mutation). Two independent sets of MUC13 siRNAs were utilized to control for potential off-target effects. Each set of MUC13 siRNA reduced MUC13 protein expression by~95% in these cell lines ( Supplementary Fig. S2A ) and resulted in significant reduced cellular β-catenin, including within the nucleus, upon LiCl treatment (which stimulates the Wnt pathway by inhibiting GSK-3β) when compared with control siRNA, as measured by immunofluorescence staining (Fig. 5a ). Based on the effect on nuclear translocation of β-catenin, we further investigated the role of MUC13 in Wnt/TCF transcriptional activity in CRC cells using a luciferase reporter assay. MUC13 knockdown significantly inhibited β-catenin transcriptional activity in these two colon cancer cell lines ( Fig. 5b ), whereas overexpression of MUC13 in SW480 cells (SW480-MUC13, Supplementary Fig. S2B ) promoted β-catenin transcriptional activity ( Supplementary Fig. S2C ).
To elucidate the consequences of reduced β-catenin-driven transcriptional activity in MUC13 silenced cancer cells, we assessed β-catenin target genes that control cell cycle (cyclin D1 and C-Myc), invasion (MMP7), and survival (survivin). Western blot analysis demonstrated that silencing MUC13 markedly suppressed Wnt target protein expression in LS513 cells ( Fig. 5c ), confirming results of the transcription reporter assay. This suggests that enhanced β-catenin transcriptional activity driven by MUC13 is a mechanism that promotes cell proliferation, invasion, and survival in colon cancer cells.
To assess the underlying molecular mechanism for the accumulation of cellular β-catenin and promotion of β-catenin-dependent transcriptional activity by MUC13, we assessed whether MUC13 is present within the β-catenin destruction complex. Co-immunoprecipitation experiments demonstrated that MUC13 associates with GSK-3β in LS513 and SW480-MUC13 cells (Fig. 5d ). The specificities of these interactions were confirmed by reverse immunoprecipitation of MUC13 ( Fig. 5d ). To determine whether MUC13 regulates the interaction between GSK-3β and β-catenin, native SW480 cells with undetectable levels of MUC13 were transfected to overexpress MUC13, and lysates immunoprecipitated with anti-GSK-3β then analyzed for the presence of GSK-3β-bound β-catenin. Overexpression of MUC13 decreased the interaction between GSK-3β and β-catenin compared with control vector-transfected cells (Fig. 5e ). Together, these results suggest that MUC13 binds to GSK-3β or another member of the complex disabling this critical β-catenin degradation enzyme, and leading to increased accumulation, nuclear translocation, and transcriptional activity of β-catenin. It is important to consider that this amplification of β-catenin activity by MUC13 occurs in the presence of mutations in APC or β-catenin itself which occur frequently in CRC [37] .
Muc13 inhibits recruitment of DC and CD8 T cells and promotes infiltration of MDSCs to AOM-DSS tumors
The Wnt/β-catenin pathway is also known to inhibit antitumor immunity and specifically the production of chemokines necessary for DC recruitment [6] . DCs, especially the Batf3-lineage DCs characterized by CD103 expression are essential for cross-presentation of tumor antigens to CD8 + T cells in the tumor-draining lymph nodes (TdLNs) to initiate anticancer immune responses [38] [39] [40] . We therefore assessed impact of Muc13 loss on the recruitment of DCs in primary colonic tumors in the CAC model and in the mesenteric TdLNs. CD103 + DCs were selectively increased in Muc13-deficient tumors (~3-fold increase) and TdLNs Fig. 6a and Supplementary Fig. S3 ), accompanied by increased CD8 + T cells (~2-fold increase, Fig. 6b and Supplementary Fig. S3 ). In contrast, Muc13 deficiency suppressed infiltration of CD11b + Lys6G hi F4/80 − granulocytic-myeloid-derived suppressor cells (G-MDSC) [41, 42] by~2-fold ( Fig. 6c and Supplementary Fig. S3 ).
Differential expression of key immune responseregulating chemokines and cytokines between WT and Muc13 −/− tumors Given the Muc13-dependent changes in these critical immune populations, we sought to establish the contribution of Muc13 to the inflammatory phenotype within AOM/ DSS tumors. The absence of Muc13 led to increased mRNA expression of genes associated with antitumor immunity including IFN-γ, FasL, Gzmb, Cxcr3, Ccl4 (a chemokine responsible for recruitment of CD103 + DC into the tumor in the absence of Wnt/β-catenin signaling [6] ), and Cxcl9 (a IFN-γ-induced CXCR3-activating ligand produced by CD103 + DCs and involved in T cell recruitment [43] ) (Fig.  7a) , and decreased expression of factors involved in recruitment and activation of MDSC to tumors and typically associated with tumor-mediated immunosuppression including Tgfb, Il6, Mip-2α, Ptgs2 (encoding COX-2), and Csf2 (encoding GM-CSF) (Fig. 7a) . Consistent with the mRNA expression data, significantly increased concentrations of IL-6 and MIP-2α were detected in conditioned media (CM) from disaggregated AOM/DSS tumors obtained from WT versus Muc13 −/− mice cultured in vitro for 16 h (Fig. 7b ). Together these findings suggest that Muc13 promotes local innate inflammation but suppresses antitumor immune responses. Therefore, in the absence of Muc13, antitumor immunity is more likely to arise, providing a plausible explanation for the fewer and smaller tumors seen in the Muc13 −/− mice.
To further explore mechanisms underlying Muc13mediated immunosuppression, we exposed mouse bone marrow derived mononuclear cells to conditioned medium from ex vivo cultured WT and Muc13 −/− AOM/DSS tumors in the presence or absence of LPS. Remarkably, LPS-induced production of TNFα and IL-12/23p40 was strongly inhibited by CM from WT but not Muc13 −/− tumors (Fig. 7c ), confirming the production of factors driving an immunosuppressive microenvironment in Muc13-expressing tumors. Extending the relevance of these findings to human cancer, multiple immunosuppressive genes were downregulated in MUC13 silenced human colon cancer cells, including genes encoding IL10, TGF-β, VEGF, and MMP7 whereas the TH1 effector cytokine IFNγ was increased (Fig. 7d ). Very similar changes in gene expression were seen in β-catenin silenced LS513 cells ( Supplementary Fig. S4 ), consistent with a β-cateninmediated mechanism of action for MUC13.
MUC13-expressing tumors increased cell death, there are resistant to checkpoint inhibition
Because there was more infiltration of CD103 + DC and CD8 T cells in Muc13-deficient colon tumors, and these cells are required for the efficacy of checkpoint inhibitor anti-PD-L1 Ab in melanoma [44] , we treated mice bearing AOM/DSS tumors with anti-PD-L1. Treatment with anti-PD-L1 Ab markedly reduced the number of tumors in Muc13 −/− but not WT mice, with complete tumor eradication in 7/14 Muc13-deficient mice vs no eradication in any WT mice (average of 10 tumors/colon) ( Fig. 8a, b) . The tumor-infiltrating CD8 + T cell population was significantly increased in Muc13 −/− tumors, and PD-L1 inhibition further increased CD8 + T cells within the Muc13 −/− tumors but not within WT tumors (Fig. 8c ). Taken together, these results suggest that local innate inflammation driven by Muc13 protects spontaneous colon tumors from checkpoint inhibitor immunotherapy.
Discussion
We show that overexpression of MUC13 in CRC is predictive of poor prognosis, suggesting that MUC13 is involved in cancer progression and/or resistance to treatment, and is a useful prognostic marker. We have previously shown a similar correlation between MUC13 expression and poor prognosis in renal cell carcinoma (RCC) patients [23] . We further demonstrated in a murine mutagen and an inflammation-driven CRC model, that Muc13 plays a key role in CRC progression and its oncogenic roles involves tumor initiation, progression to invasive carcinoma, and establishment of innate inflammation protecting cancers from immune attack. In addition, we reveal multiple underlying mechanisms by which MUC13 promotes cancer development, demonstrating that MUC13 is an important promoter of Wnt/β-catenin signaling, even in the context of the classical molecular defects in this pathway in CRC. These findings advance previous reports identifying MUC13 as a driver of aggressive behavior in ovarian, gastric, and pancreatic cancers [17, 22, 24] , and as a promising therapeutic target.
We chose to investigate the role of Muc13 in the AOM/ DSS model, because this model has proven to recapitulate the aberrant crypt foci-adenoma-carcinoma sequence [30] that occurs in human CRC and gives large numbers of spontaneously arising colonic tumors [30] which presents the similarities with human CRC pathogenesis. In addition, tumors arising in the AOM/DSS model commonly have dysregulation of the APC/β-catenin signaling pathway, such as altered cellular localization of β-catenin driven by mutations in APC and/or β-catenin [30] . The AOM/DSS model has also been used to interrogate the link between inflammation and cancer development in the colon [32] . Muc13 was required to protect epithelial cells from excessive DSS-induced cell death, as we previously described in an acute DSS-colitis model [27] . However, somewhat unexpectedly given the increased cell death and thus need for wound repair, there was less cell proliferation in Muc13 −/− intestines 4 days after the first DSS exposure. Taken together, the increased number of tumors in WT mice in the chronic AOM/DSS model may be attributable to enhanced survival of AOM-mutated cells when exposed to the DSS-induced stress, enlarging the pool of potential tumor-initiating stem cells. This suggests that the mechanism driving Muc13-dependent tumorigenesis is the ability of Muc13 to regulate cell death and proliferation. Indeed, induction of the Bcl-XL protein, which is regulated by both NFκB and β-catenin, is a common observation during the early mucosal response to the DSS insult [32] that was absent in Muc13 −/− mice. Although administration of a Bcl-XL inhibitor during AOM/DSS-induced colitis did not reduce tumor load in either WT or Muc13 −/− mice, it is possible that in vivo delivery of the inhibitor may have induced apoptosis of tumor immune-mediators such as CD8 + T cells.
Constitutive nuclear β-catenin expression and overactivated Wnt/β-catenin signaling promotes growth, invasion, and metastasis in CRC [45, 46] . Our finding that MUC13 stabilizes β-catenin, enhancing its nuclear translocation and transcriptional activity, highlighted the pivotal role of MUC13 in promoting CRC progression. Our data showed that MUC13 is present in the β-catenin complex together with GSK-3β, the enzyme critical for β-catenin degradation. MUC13 may interact directly with GSK-3β or via another complex member, preventing its ability to initiate β-catenin degradation, leading to accumulation of β-catenin and promotion of Wnt/β-catenin signaling. Importantly, we demonstrate that MUC13 strongly influences β-catenin accumulation even in the context of tumors with APC or β-catenin mutations. Interestingly, a reduction in phosphorylation of NFκB p65 was also detected in Muc13 −/− tumors vs WT tumors, consistent with our previous reports that MUC13 enhances NFκB signaling in response to DNA damage in human CRC and RCC cells [23, 29] . MUC13 has also been shown to increase expression of the HER2/c-erbB2 growth factor receptor in ovarian and pancreatic cancers, and contributes to cancer progression by interacting with HER2 activating downstream signaling pathways [22, 24, 47] . Taken together, MUC13 is linked to the activation of several pathways known to be of important for cancer development. We propose that in an environment with high β-catenin activity, such as in intestinal adenocarcinoma, MUC13 can impede GSK-3β-mediated β-catenin degradation. Thus, we suggest that MUC13 is a novel stabilizer of β-catenin and promotes its nuclear translocation and transcriptional activity, thereby promoting proliferation and invasion, two hallmarks of cancer development. Both MUC1 and MUC4 have been shown to promote nuclear localization of β-catenin in gastrointestinal and pancreatic cancers [48, 49] . Together with our findings these studies suggest that the cell surface mucin family is broadly involved in intricate regulatory relationships with β-catenin in normal epithelium, enhanced by depolarization of damaged epithelium with their interactions promoting nuclear localization of β-catenin and Wnt signaling driving the proliferation and migration required during epithelial wound repair. High expression of the mucins in adenocarcinomas thereby promotes a wound repair phenotype which enhances tumor development and progression. The relative and combined importance (where co-expressed) of these mucins in CRC and other adenocarcinomas is therefore worthy of further investigation.
CRC originates within an immunologically complex microenvironment and is characterized by intrinsic innate inflammation. This is particularly relevant with regard to right sided mismatch repair-deficient (MMR) colorectal cancers, which are more likely to have tumor-infiltrating lymphocytes [50] . Interestingly, MUC13 expression is significantly higher in left-sided tumors than right-sided tumors [18] . To date, despite a high mutational load, classical microsatellite stable cancer has proven resistant to Fig. 5 MUC13 promotes β-catenin stabilization and activity by interacting with the GSK-3β complex. a Immunofluorescence staining for β-catenin (red) and nuclei (DAPI, blue) in LS513 and HT29 cells ± MUC13 siRNA silencing with or without LiCl (10 mM) treatment for 4 h to activate β-catenin. Fluorescence intensity of β-catenin colocalization with DAPI was determined using an Olympus FV1200 microscope, n > 100 cells. b β-catenin-driven transcriptional activity was measured using the Cignal lenti TCF/LEF reporter luciferase assay in cells treated silenced as in a but with β-catenin activated by CHIR-99021 GSK-3β-inhibitor at 1 µM for 4 h. c Immunoblot analysis of β-catenin-regulated tumor promoting proteins in cells treated with CHIR-99021 (1 µM) for 24 h. d Co-immunoprecipitation of GSKβ with MUC13 in native LS513 cells, and SW480 cells stably transfected with MUC13. e Immunoblots for β-catenin is immunoprecipitates of GSKβ and β-catenin in SW480 cells with and without expression of MUC13. Statistics: a, b mean ± SEM. a One-way ANOVA with Tukey post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001. The data are representative of three independent experiments. See Supplementary Fig. S2A for verification of MUC13 silencing, and S2B for MUC13 overexpression in SW480 cells promoted β-catenindriven transcriptional activity checkpoint blockade immunotherapies, whereas neoantigen-rich MMR cancer is responsive to these therapies. Immunotherapy alone is insufficient for treating advanced CRC and presence of innate inflammation in these tumors has been associated with poor prognosis and likely suppresses antitumor immunity.
On the other hand, CD8 + T cell infiltration has been associated with an improved tumor prognosis and response to immune checkpoint blockade, but the mechanisms regulating immune cell infiltration are largely undetermined. We report here a strong association between Muc13 and a lack of both the cross-presentating DC that initiate tumor immunity (CD103 + DC) and cytotoxic CD8 + T cells responsible for killing tumor cells. In melanoma, nuclear translocation of β-catenin has been shown to inhibit AFT3 transcription and limit secretion of chemokines, including CCL4, that promote migration of CD103 + DC [6] . Similarly, Muc13-mediated β-catenin activation Supplementary Fig. S3 for the gating strategy to identify CD103 + DCs and MDSC reduced tumor recruitment of CD103 + DC in our study, leading to defective CD8 + T cell priming and tumor infiltration. In addition, in Muc13 +/+ mice there is a substantial increase in G-MDSC which are known to inhibit T cell proliferation and cytotoxic activity, promote T regulatory cell activity, and promote tumorigenesis in the AOM/DSS CAC model [42, 51] . The mechanism by which MUC13 modulates immunosuppression is likely by promotion of β-catenin activation since the changes in expression of immunosuppressive/inflammatory genes in human colon cancer cells were very similar when MUC13 and β-catenin were silenced. Taken together, the altered tumor inflammatory microenvironment we report in the absence of Muc13 could explain the reduction in tumor formation and lower grade of the surviving tumors, with more heavily mutated tumors most likely eradicated by immunity.
The observed relationship between Muc13 and an immunosuppressive environment in AOM/DSS tumors is consistent with the resistance of WT mice to checkpoint inhibition with anti-PD-L1 whilst Muc13-deficient mice were susceptible, with 7/14 tumors completely eradicated. We previously demonstrated in preclinical immunodeficient xenograft models that targeting MUC13 sensitizes CRC to chemotherapy [29] , and now show that Muc13 deficiency renders sensitivity to tumors resistant to checkpoint inhibition. Muc13 −/− mice do not have any clear phenotype under normal conditions, suggesting that targeting MUC13 may not have adverse effects, although this remains to be formally tested. AOM/DSS tumors are intrinsically heterogeneous, and there was heterogeneity in the response to anti-PD-L1 which requires further exploration in relation to the inflammatory phenotype within responding and nonresponding tumors. Together, these data suggest that strategies to inhibit MUC13 expression or function are likely to promote antitumor immunity and the efficacy of checkpoint blockade, and potentially other immunotherapies, in MUC13expressing tumors characterized by innate inflammation.
In summary, our study has identified novel roles and mechanisms of MUC13 in colonic tumorigenesis and progression. Our data reveal a multifaceted role for MUC13 expression by colonic neoplasms: to promote tumor initiation and growth directly by inhibiting neoplastic epithelial cell death; to stimulate proliferation and migration; and to suppress immune recognition of tumors by modulating the tumor microenvironment, inhibiting DC and CD8 T cell recruitment and promoting recruitment of immunosuppressive MDSC cells.
Materials and methods
Patient's samples
Cohort 1
A colon cancer TMA spotted with 93 cases/180 cores (# HCol-Ade180Sur-02; 88 cases with OS (months) information) was purchased from US Biomax, Inc. (Biomax, Rockville, MD, USA). The expression of MUC13 was analyzed in all the 88 cases by IHC with the anti-MUC13 polyclonal antibody (R20C1) following previously published methods [18, 25, 29] . The stained slides were scored blindly by a histopathologist (RL) according to a scoring system as follows: the proportion of positive cancer cell staining was graded 0 (negative), <25% (1+), 25-50% (2+), 50-70% (3+), and >75% (4+); and the staining intensity of cancer cells was graded as negative (0), weak (1+), moderate (2+), strong (3+), or very strong (4+). The proportion and intensity scores were added to give an overall staining score. Staining scores ≥5 was classified as high-MUC13 expression, whilst scores ≤4 were considered low-MUC13 expression. The patients' clinical data and the scores of MUC13 expression in the TMA are presented in Supplementary Table S1 .
Cohort 2
In addition, primary CRC patients who had not achieved remission (CDE: 3103479; therapy ongoing statusespatients who were undergoing chemo-, radio-, or biologytherapy) were assigned into two subgroups, with low (n = 200) and high-MUC13 expression (n = 50). The MUC13 high-expression subgroup was defined as the top 20% of the gene's expression range within the cohort. The UCSC Xena Browser [52] was used to obtain normalized gene expression values, represented as log 2 (fpkm-uq+1), from the National Cancer Institute Genomic Data Commons The Cancer Genome Atlas colorectal data set (denoted GDC TCGA-COAD) [53, 54] . OS information was obtained from GDC release 9.0 (released on the 25th of October 2017). The patients' clinical data and the MUC13 expression in the cohort 2 are presented in Supplementary Table S2 .
Mice
Muc13 +/+ (wild type) and Muc13 −/− mice on C57BL/6 background were bred at Mater Research Institute-The University of Queensland, Translational Research Institute or Herston Medical Research Institute, Queensland 4102, Australia. The experiments involving mice were conducted in accordance with the Australian Code for the Care and Use of Animals for Scientific Purposes 8th edition (2013) and were approved by University of Queensland Animal Experimentation Ethics Committee. Mice were sex and age matched within experiments (6-12 weeks of age, n = 8-15).
Tumor induction, analysis, and treatment
Colon tumors were induced by the AOM and the DSS model ( Fig. 2a ). Briefly, mice were injected intraperitoneally with 10 mg AOM (A5486; Sigma-Aldrich, St. Louis, MO) per kg body weight. Seven days later, 1.5% DSS (molecular mass 36-40 kDa) was given in the drinking water for 5 days followed by regular drinking water for 2 weeks. This cycle was repeated once with 1.5% DSS, and mice were sacrificed on day 84. The researcher who dissected the colons and counted tumors was blinded to the treatment. Colon tissues were fixed in 10% formalin, embedded in paraffin, sectioned, and stained with H&E. For Day 12 samples, mice were injected with AOM, and after 7 days, they were fed with 1.5% DSS for 5 days before mice were sacrificed. For day 16 samples, mice were injected with AOM, and after 7 days, they were fed with 1.5% DSS for 5 days. Mice were then fed with regular water for 4 days. The number of proliferating cells in the intestinal epithelium was detected by BrdU as described below and previously [29] . Apoptosis was determined using a terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining assay (Roche, Indianapolis, IN).
Cages of wild type or Muc13 −/− mice were allocated to treatment groups by random draw. Bcl-XL inhibition treatments started from Day 12 after AOM/DSS (mice were injected with AOM, and after 7 days, they were fed with 1.5% DSS for 5 days) with AB-263 (40 mg/kg oral gavage, twice weekly). Anti-PD-L1 antibody treatment started from day 42 after AOM/DSS (100 µg i.p., twice weekly).
Cell culture
Human LS513, SW480, and HT29 intestinal epithelial cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and propagated in RPM1-1640 (Life technologies, Carlsbad, CA) with 10% heat inactivated fetal calf serum, 100 U ml −1 penicillin, 100 μg ml −1 streptomycin, and 2 mM L-glutamine. All these cell lines have been authenticated by short tandem repeat profiling, and they are mycoplasma free and the number of passages do not exceed five times.
Statistical analysis
All statistical analyses were performed using Prism v5 (Graphpad Software). Sample sizes for experiments were determined by power analyses based on the variation shown in previous experiments and predicted effect sizes considered to be of biological relevance. No data were excluded from any analyses. The normal distribution of data was assessed by probability plots and where a normal distribution could not be established nonparametric testing was used. The statistical test used and the sample sizes for individual analyses are provided within the figure legends.
